Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adalimumab vs Infliximab in RA with Unsustainable Response
NCT00216177Phase 4Unknown
- Sponsor
- Copenhagen University Hospital - Hvidovre
- Start
- Sep 2005
- Primary completion
- Jan 2009
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of adalimumab in rheumatoid arthritis (RA) (2 arms), sponsored by Copenhagen University Hospital - Hvidovre. Primary endpoint: Proportion of patients achieving combined good or moderate EULAR responses at 24 weeks. Status: unknown.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT00216177.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00216177.